Núcleo de biomarcadores y tecnologías avanzadas
Joan Berman, PhD
Director (Einstein)
Professor of Pathology, and Microbiology and Immunology; Irving D. Karpas Chair in Medicine
Steven Almo, PhD
Director (Einstein)
Chair and Professor of Biochemistry; Wollowick Family Foundation Chair in Immunology
James Kreuger, MD, PhD
Co-Director (Rockefeller)
D. Martin Carter Professor in Clinical Investigation; Co-Director of the Center for Clinical and Translational Science
Para contribuir al objetivo del gobierno de los Estados Unidos de poner fin a la epidemia del VIH (EHE), el Centro Einstein-Rockefeller-CUNY para la Investigación del SIDA (ERC-CFAR) del Centro de Biomarcadores y Tecnología Avanzada (BATC) proporciona tecnologías, servicios y consultas de vanguardia para mejorar nuestra comprensión de la biología y los mecanismos del VIH, y acelerar el desarrollo de nuevos enfoques para su prevención y cura. El BATC apoya a investigadores en ciencias básicas, traslacionales, clínicas y de implementación que desarrollan y evalúan nuevas modalidades para tratar y prevenir la infección por VIH, incluyendo estrategias para mejorar la eficacia de la profilaxis preexposición (PrEP), la profilaxis posexposición (PEP) y el tratamiento como prevención (TasP).
The BATC infrastructure supports established and early stage HIV/AIDS researchers as well as new investigators who are expanding their research to include HIV/AIDS-related studies at Einstein, Rockefeller, and CUNY. The Core leadership provides unique consultation services that leverage their experience to facilitate research by ERC-CFAR investigators and to identify collaborative opportunities within and outside the BATC. The BATC provides cutting-edge services to enable our investigators including members of the HIV and Mental Health Scientific Working Group to accomplish their research, mentors and trains the next generation of HIV investigators, supports the recruitment of established investigators into HIV research, and forges new collaborations across Einstein, Rockefeller and CUNY and other regional academic centers.
Servicios
The BATC offers a broad range of services as well as the ability to develop new services customized to your needs. We welcome your inquiries! Please contact us to initiate a consultation which is free of charge, as are some other services to ERC-CFAR members. ERC-CFAR members benefit from a preferential fee structure for Core services, but the Core provides services to those who are not ERC-CFAR members as well.
Technological support for HIV prevention, treatment, pathogenesis and cure research
- Biomarker assays and measurement of antiretroviral therapy (ART) adherence
- Analysis of fluids from in vitro (cell and tissue culture), in vivo (animal models) and clinical samples for quantification of immune molecules linked to HIV pathogenesis, HIV risk and comorbidities using multiplex and ELISA assays.
- Assays to quantify antiretroviral drug levels (pharmacokinetics), and antiretroviral drug activity (pharmacodynamics) using mass spectrometry, and functional antiviral studies.
- Provision of peripheral blood mononuclear cells (PBMC) and specific subpopulations of cells (e.g. CD4 and/or CD8 T cells, monocytes, macrophages) isolated from human leukopaks, including samples obtained in collaboration with the Clinical and Translational Science Core (CTSC) by leukapheresis of patients from Montefiore and Rockefeller living with or at risk for HIV infection with defined clinical characteristics.
- Establishment of cutting-edge research technologies as Core services to provide new opportunities to investigators such as an ex vivo blood-brain model for evaluating virus or factor entry into the brain.
Protein sciences support to pursue a wide range of mechanistic studies central to understanding HIV biology and treatment.
- Production of critical protein reagents to support development of novel biologics for HIV treatment and cure using our well-established bacterial, insect and mammalian expression platforms.
- Synthesis of protein antigens to study cellular and humoral immunity including the large quantities needed for structural and biochemical characterization of proteins and assemblies critical for HIV infection and life cycle.
- Provision of unique cell-based assays for characterizing receptor-ligand interactions, including those relevant to novel discoveries linked to antibody dependent cell mediated cytotoxicity (ADCC), a critical aspect of vaccines and immunotherapies.
Implementation and evaluation of new technologies for inclusion within BATC.
- Nuevos servicios implementados: Soporte bioinformático para RNAseq, scRNAseq y otros estudios transcriptómicos, y ensayos de biomarcadores adicionales para la adherencia a PrEP y TAR.
- Servicios en evaluación: metabolómica ampliada/cuantificación de moléculas pequeñas, análisis del microbioma y proteómica.
- Extensive consultation services to enable investigators to access new technologies not provided within the BATC, but which are available at other institutions.
Luminex Assays
As part of the Biomarker Core, the Herold lab will conduct multiplex assays using a state of the art Luminex xMAP Instrument. The instrument runs both 96 and 384 well plates andhas updated lasers and detectors to enable detection of 500 bead regions per well. The machine allows investigators to quantify multiple analytes in a single sample of patient serum, plasma or CSF, animal blood, culture supernatants, cell lysates, and others. This includes quantification of biomarkers of inflammation, innate immunity, apoptosis, and activation of signaling pathways. Please contact the Herold lab for more information including CFAR and non-CFAR pricing options.
Para obtener más información o acceder a los servicios básicos de Biomarcadores y Tecnologías Avanzadas, comuníquese con los Dres. Berman , Almo, or Kreuger.